8 news items
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
AKRO
ETNB
LLY
5 Jun 24
endpoint.
Larger and longer trials are needed to assess the efficacy and safety of tirzepatide for non-cirrhotic MASH
What's Going On With Viking Therapeutics Stock On Tuesday?
VKTX
4 Jun 24
highlight the achievement of secondary endpoints evaluating histologic changes assessed by hepatic biopsy after 52 weeks of treatment with VK2809
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
VKTX
4 Jun 24
announced today highlight achievement of secondary endpoints evaluating histologic changes assessed by hepatic biopsy after 52 weeks of treatment
Ligand Reports First Quarter 2024 Financial Results
AMGN
CASI
JAZZ
7 May 24
to report data on histologic changes assessed after 52 weeks of treatment later in the second quarter of 2024
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
VKTX
24 Apr 24
and safety profile. We plan to report data on histologic changes assessed after 52 weeks of treatment later this quarter. Finally, during the first
gb6keg4
VKTX
9 Apr 24
to $90.0 for Viking Therapeutics over the recent three months.
Volume & Open Interest Trends
Assessing the volume and open interest
jf1rivdka24t7enai cl62h1agfdwp78t62o9q9hen4bqh0zudusocxzqu
VKTX
26 Mar 24
, ranging up to 3.6% relative to placebo.
An exploratory assessment of the proportion of subjects achieving at least 5% weight loss after
gvgj7eeiqanp9xlu6s6z5xgr4p89tnohx0
VKTX
26 Mar 24
after the last dose of VK2735 was administered, ranging up to 3.6% relative to placebo. An exploratory assessment of the proportion of subjects
- Prev
- 1
- Next